Literature DB >> 22535504

Renal cell carcinoma deep sequencing: recent developments.

Leslie J Farber1, Kyle Furge, Bin Tean Teh.   

Abstract

Renal cell carcinoma (RCC) is the most common type of renal cancer in adults. RCC is notoriously resistant to current therapies suggesting the need to improve our knowledge and create more effective therapies. The molecular genetic defects that occur in RCC are extensive and complex ranging from single DNA changes, to large chromosomal defects, to signature disruptions in the transcription of hundreds of genes. These changes are often shared within each histological RCC subtype, illustrating their significance to the disease phenotype. This review presents an overview of the genetic abnormalities that occur within the most common subtypes of RCC. We discuss the recent molecular findings that have advanced our understanding of the somatic architecture of renal tumors and their impact on disease therapeutics.

Entities:  

Mesh:

Year:  2012        PMID: 22535504     DOI: 10.1007/s11912-012-0230-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  114 in total

1.  Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array.

Authors:  J M Boer; W K Huber; H Sültmann; F Wilmer; A von Heydebreck; S Haas; B Korn; B Gunawan; A Vente; L Füzesi; M Vingron; A Poustka
Journal:  Genome Res       Date:  2001-11       Impact factor: 9.043

2.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

3.  The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Authors:  X Niu; T Zhang; L Liao; L Zhou; D J Lindner; M Zhou; B Rini; Q Yan; H Yang
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

4.  Prognostic implications of cytogenetic findings in kidney cancer.

Authors:  P Elfving; N Mandahl; R Lundgren; J Limon; E Bak-Jensen; M Fernö; H Olsson; F Mitelman
Journal:  Br J Urol       Date:  1997-11

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.

Authors:  Matthias Waldert; Andrea Haitel; Michael Marberger; Daniela Katzenbeisser; Mehmet Ozsoy; Elisabeth Stadler; Mesut Remzi
Journal:  BJU Int       Date:  2008-09-08       Impact factor: 5.588

7.  Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas.

Authors:  A Kovacs; S Storkel; W Thoenes; G Kovacs
Journal:  J Pathol       Date:  1992-07       Impact factor: 7.996

8.  Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma.

Authors:  Matteo Brunelli; Albino Eccher; Stefano Gobbo; Vincenzo Ficarra; Giacomo Novara; Paolo Cossu-Rocca; Franco Bonetti; Fabio Menestrina; Liang Cheng; John N Eble; Guido Martignoni
Journal:  Mod Pathol       Date:  2007-09-28       Impact factor: 7.842

9.  Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3.

Authors:  Mark P Purdue; Mattias Johansson; Diana Zelenika; Jorge R Toro; Ghislaine Scelo; Lee E Moore; Egor Prokhortchouk; Xifeng Wu; Lambertus A Kiemeney; Valerie Gaborieau; Kevin B Jacobs; Wong-Ho Chow; David Zaridze; Vsevolod Matveev; Jan Lubinski; Joanna Trubicka; Neonila Szeszenia-Dabrowska; Jolanta Lissowska; Péter Rudnai; Eleonora Fabianova; Alexandru Bucur; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Paolo Boffetta; Joanne S Colt; Faith G Davis; Kendra L Schwartz; Rosamonde E Banks; Peter J Selby; Patricia Harnden; Christine D Berg; Ann W Hsing; Robert L Grubb; Heiner Boeing; Paolo Vineis; Françoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Eric J Duell; José Ramón Quirós; Maria-José Sanchez; Carmen Navarro; Eva Ardanaz; Miren Dorronsoro; Kay-Tee Khaw; Naomi E Allen; H Bas Bueno-de-Mesquita; Petra H M Peeters; Dimitrios Trichopoulos; Jakob Linseisen; Börje Ljungberg; Kim Overvad; Anne Tjønneland; Isabelle Romieu; Elio Riboli; Anush Mukeria; Oxana Shangina; Victoria L Stevens; Michael J Thun; W Ryan Diver; Susan M Gapstur; Paul D Pharoah; Douglas F Easton; Demetrius Albanes; Stephanie J Weinstein; Jarmo Virtamo; Lars Vatten; Kristian Hveem; Inger Njølstad; Grethe S Tell; Camilla Stoltenberg; Rajiv Kumar; Kvetoslava Koppova; Olivier Cussenot; Simone Benhamou; Egbert Oosterwijk; Sita H Vermeulen; Katja K H Aben; Saskia L van der Marel; Yuanqing Ye; Christopher G Wood; Xia Pu; Alexander M Mazur; Eugenia S Boulygina; Nikolai N Chekanov; Mario Foglio; Doris Lechner; Ivo Gut; Simon Heath; Hélène Blanche; Amy Hutchinson; Gilles Thomas; Zhaoming Wang; Meredith Yeager; Joseph F Fraumeni; Konstantin G Skryabin; James D McKay; Nathaniel Rothman; Stephen J Chanock; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2010-12-05       Impact factor: 38.330

Review 10.  BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports.

Authors:  J R Toro; M-H Wei; G M Glenn; M Weinreich; O Toure; C Vocke; M Turner; P Choyke; M J Merino; P A Pinto; S M Steinberg; L S Schmidt; W M Linehan
Journal:  J Med Genet       Date:  2008-01-30       Impact factor: 6.318

View more
  6 in total

1.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

2.  VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.

Authors:  Sang Hoon Song; In Gab Jeong; Dalsan You; Jun Hyuk Hong; Bumsik Hong; Cheryn Song; Woon Yong Jung; Young Mee Cho; Hanjong Ahn; Choung-Soo Kim
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

3.  Papillary renal cell carcinoma: a clinicopathological and whole-genome exon sequencing study.

Authors:  Kunpeng Liu; Yuan Ren; Lijuan Pang; Yan Qi; Wei Jia; Lin Tao; Zhengyan Hu; Jin Zhao; Haijun Zhang; Li Li; Haifeng Yue; Juan Han; Weihua Liang; Jianming Hu; Hong Zou; Xianglin Yuan; Feng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 4.  The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma.

Authors:  Ana Lameirinhas; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Genes (Basel)       Date:  2019-04-02       Impact factor: 4.096

5.  Proliferation inhibition and the underlying molecular mechanisms of microRNA-30d in renal carcinoma cells.

Authors:  Hongsheng Yu; Xialu Lin; Fang Wang; Burong Zhang; Weihua Wang; Hongbo Shi; Baobo Zou; Jinshun Zhao
Journal:  Oncol Lett       Date:  2013-12-11       Impact factor: 2.967

6.  Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells.

Authors:  Sheng-Tang Wu; Wei-Chi Ku; Chi-Jung Huang; Yen-Chieh Wang; Chih-Ming Lin; Shao-Kuan Chen
Journal:  J Biomed Sci       Date:  2016-09-29       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.